An affordable and accessible solution for patients with diabetes on the market: Prpms-DAPAGLIFLOZIN from Pharmascience Canada

Pharmascience Canada launches the generic Prpms-DAPAGLIFLOZIN in the Canadian market.

Prpms-DAPAGLIFLOZIN is primarily used along with diet and exercise to:

  • improve blood sugar levels in adults with type 2 diabetes. Prpms-DAPAGLIFLOZIN can be used alone, with metformin, with a sulfonylurea, with metformin and a sulfonylurea, with sitagliptin (with or without metformin), or with insulin (with or without metformin).
  • reduce the risk of hospitalization due to heart failure in in adults with type 2 diabetes and that have or are at risk of developing cardiovascular disease (heart and blood vessel problems)

Prpms- DAPAGLIFLOZIN is also used (i) in adults along with other medicines to treat heart failure to reduce the risk of death due to cardiovascular problems, and to reduce the risk hospitalization or urgent visits due to heart failure, and (ii) in adults with chronic kidney disease to reduce their risk of further decline in kidney function, progression to end-stage kidney disease and death due to cardiovascular problems or kidney failure.

With the same safety and efficacy profile as the brand-name product, the Prpms-DAPAGLIFLOZIN 5 mg and 10 mg oral tablets are available at a lower price.

“At Pharmascience, we take tremendous pride in providing support and high-quality solutions for all our patients. With the addition of Prpms-DAPAGLIFLOZIN, a generic equivalent to PrForxiga®, to our portfolio of diabetes therapeutic class products, patients with type 2 diabetes in Canada can now benefit from an affordable and accessible option to help manage their disease,” said Mike Dutton, Vice President, and General Manager of Pharmascience Canada.



Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada’s top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People as part of Canada’s Top 100 Employers. Pharmascience is now certified as a Great Place to Work for a second year in a row.

PrForxiga® is a registered trademark of AstraZeneca Canada Inc.

Published in

Product Launches